Jaguar Health reports positive preliminary open-label crofelemer study results in adult short bowel syndrome patients with intestinal failure
Bitget2026/10/14 13:00- Jaguar Health highlighted preliminary findings already presented Oct. 13, 2026 at the ACG meeting from an open-label crofelemer study in adult SBS-IF.
- Early results showed some patients improved on treatment, with output worsening in several cases once therapy stopped.
- Safety profile looked favorable, with no significant adverse events reported in participants who completed the protocol.
- A randomized, double-blind Phase 2 trial in adult Type 1 SBS is underway, with results expected early in the second half of 2027.
- The intestinal-failure program targets reduced reliance on parenteral support, with an MVID NDA filing planned for mid-2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.
Why Nintendo Stock Is One to Watch Ahead of the Holiday Season
A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.
Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.
Crypto prices
More
